Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry

JACC: Heart Failure

Volumn 7, Issue 4, 2019, Pages 350-358

  Peri Okonny, Poghni A ^a   Mi, Xiaojuan ^b   Khariton, Yevgeniy ^a   Patel, Krishna K ^a   Thomas, Laine ^b   Fonarow, Gregg C ^c   Sharma, Puza P ^d   Duffy, Carol I ^d   Albert, Nancy M ^e   Butler, Javed ^f   Hernandez, Adrian F ^b   McCague, Kevin ^d   Williams, Fredonia B ^g   DeVore, Adam D ^b   Patterson, J Herbert ^h   Spertus, John A ^a,i  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MISSISSIPPI   (United States)

^g Mended Hearts   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

heart failure; systolic blood pressure; target dose

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; MINERALOCORTICOID ANTAGONIST;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE REGISTRY; FEMALE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MIDDLE AGED; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; UNITED STATES; VERY ELDERLY; BLOOD PRESSURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; HEART FAILURE; HEART STROKE VOLUME; HOSPITALIZATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; REGISTER; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; STROKE VOLUME; TREATMENT OUTCOME;

EID: 85062943603     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2018.11.011     Document Type: Article

References (38)

1. Benjamin, E.J., Blaha, M.J., Chiuve, S.E., et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135 (2017), e146–e603.
2. Sacks, C.A., Jarcho, J.A., Curfman, G.D., Paradigm shifts in heart-failure therapy — a timeline. N Engl J Med 371 (2014), 989–991.
3. Colucci, W.S., Packer, M., Bristow, M.R., et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 94 (1996), 2800–2806.
4. Packer, M., Fowler, M.B., Roecker, E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002), 2194–2199.
5. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70 (2017), 776–803.
6. Packer, M., McMurray, J.J., Desai, A.S., et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (2015), 54–61.
7. Packer, M., Poole-Wilson, P.A., Armstrong, P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100 (1999), 2312–2318.
8. Bristow, M.R., Gilbert, E.M., Abraham, W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996), 2807–2816.
9. Fiuzat, M., Wojdyla, D., Kitzman, D., et al. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol 60 (2012), 208–215.
10. Bhatt, A.S., DeVore, A.D., DeWald, T.A., Swedberg, K., Mentz, R.J., Achieving a maximally tolerated beta-blocker dose in heart failure patients: is there room for improvement?. J Am Coll Cardiol 69 (2017), 2542–2550.
11. Heywood, J.T., Fonarow, G.C., Yancy, C.W., et al. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail 3 (2010), 596–605.
12. Parwani, P., Ryan, J., Heart failure patients with low blood pressure: how should we manage neurohormonal blocking drugs?. Circ Heart Fail, 5, 2012, 819.
13. DeVore, A.D., Thomas, L., Albert, N.M., et al. Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. Am Heart J 189 (2017), 177–183.
14. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
15. Konstam, M.A., Neaton, J.D., Dickstein, K., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374 (2009), 1840–1848.
16. Ouwerkerk, W., Voors, A.A., Anker, S.D., et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38 (2017), 1883–1890.
17. Anand, I.S., Rector, T.S., Kuskowski, M., Thomas, S., Holwerda, N.J., Cohn, J.N., Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial. Circ Heart Fail 1 (2008), 34–42.
18. Bohm, M., Young, R., Jhund, P.S., et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J 38 (2017), 1132–1143.
19. Montero-Perez-Barquero, M., Flather, M., Roughton, M., et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. Eur J Heart Fail 16 (2014), 1009–1015.
20. Wikstrand, J., Hjalmarson, A., Waagstein, F., et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 40 (2002), 491–498.
21. Metra, M., Torp-Pedersen, C., Swedberg, K., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26 (2005), 2259–2268.
22. Vardeny, O., Claggett, B., Packer, M., et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail 18 (2016), 1228–1234.
23. Greene, S.J., Butler, J., Albert, N.M., et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72 (2018), 351–366.
24. Miller, A.L., Wang, Y., Curtis, J., Masoudi, F.A., Buxton, A.E., Wang, T.Y., Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: insights from the National Cardiovascular Data Registry. Arch Int Med 172 (2012), 64–67.
25. Komajda, M., Follath, F., Swedberg, K., et al. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24 (2003), 464–474.
26. Fuat, A., Hungin, A.P.S., Murphy, J.J., Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ, 326, 2003, 196.
27. Gorelik, O., Feldman, L., Cohen, N., Heart failure and orthostatic hypotension. Heart Fail Rev 21 (2016), 529–538.
28. Patel, P.A., Heizer, G., O'Connor, C.M., et al. Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. Circ Heart Fail 7 (2014), 918–925.
29. Ambrosy, A.P., Vaduganathan, M., Mentz, R.J., et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J 165 (2013), 216–225.
30. Gheorghiade, M., Vaduganathan, M., Ambrosy, A., et al. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail Rev 18 (2013), 107–122.
31. Komajda, M., Bohm, M., Borer, J.S., et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail 16 (2014), 810–816.
32. Phillips, L.S., Branch, W.T. Jr., Cook, C.B., et al. Clinical inertia. Ann Int Med 135 (2001), 825–834.
33. Curtis, L.H., Greiner, M.A., Hammill, B.G., et al. Early and long-term outcomes of heart failure in elderly persons, 2001–2005. Archives of internal medicine 168 (2008), 2481–2488.
34. Hummel, S.L., Pauli, N.P., Krumholz, H.M., et al. Thirty-day outcomes in Medicare patients with heart failure at heart transplant centers. Circ Heart Fail 3 (2010), 244–252.
35. Tsao, C.W., Lyass, A., Enserro, D., et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. J Am Coll Cardiol HF 6 (2018), 678–685.
36. Fonarow, G.C., Hernandez, A.F., Solomon, S.D., Yancy, C.W., Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure. JAMA Cardiol 1 (2016), 714–717.
37. Fonarow, G.C., Yancy, C.W., Hernandez, A.F., Peterson, E.D., Spertus, J.A., Heidenreich, P.A., Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 161 (2011), 1024–1030.e3.
38. Bonow, R.O., Ganiats, T.G., Beam, C.T., et al. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. J Am Coll Cardiol 59 (2012), 1812–1832.